Clinical trials: Diabetes Type I
Type 1 Diabetes, Type 2 Diabetes
Feasibility Study - Integrated Sensor and Infusion Set. Trial III
The purpose of this study is to collect performance data on the Integrated sensor and infusion set during 3 days of use and demonstrate performance adequacy of the integrated sensor and infusion set with glucose sensing and…
- Trial name
- NCT01773668
- Testing
- Integrated sensor and infusion set.
- Where
- Sweden
- Volunteers
- 17 people
- Sponsor
- Medtronic Diabetes R&D Denmark
Type 1 Diabetes Mellitus
A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus
The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for up to four (4) months.
- Trial name
- NCT03162926
- Testing
- VC-02 Combination Product (aka PEC-Direct)
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- ViaCyte
Diabetes, Diabetes Mellitus, Type 1
Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) of insulin degludec (insulin 454), an explorative formulation, not similar to the…
- Trial name
- NCT01865318
- Testing
- insulin degludec
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients
The purpose of this study is to investigate whether the treatment of human menstrual blood-derived mesenchymal stem cells which would be applied to diabetes patients is safe and effective.
- Trial name
- NCT01496339
- Testing
- MenSCs transplantation, exogenous indulin injection daily
- Where
- China
- Volunteers
- 50 people
- Sponsor
- S-Evans Biosciences Co., Ltd.
Diabetes Mellitus, Type 1
Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients
Insulin dependent Type I diabetics require daily insulin therapy to normalize blood glucose but may have difficulty with significant glycemic excursions and hypoglycemic episodes and crises.
- Trial name
- NCT00260234
- Testing
- Allogeneic Cultured Islet Cells (human); Encapsulated
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Novocell
Diabetes, Diabetes Mellitus, Type 1
Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate the effectiveness of Tresiba® (insulin degludec) after switching basal insulin in a population with type 1 or type 2 diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- EU-TREAT (NCT02662114)
- Testing
- No treatment given
- Where
- 7 sites in Austria, Denmark and 4 more
- Volunteers
- 2,302 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males
This study is a single-center, randomized, double-blind, placebo- and active-controlled, parallel-group, single-ascending dose (SAD) design.
- Trial name
- NCT07630233
- Testing
- UBT38006, Insulin Degludec Injection, Insulin Icodec Injection
- Where
- China
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Type 1 Diabetes Mellitus
BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study
Continuous Subcutaneous Insulin Infusion (CSII) via insulin pump therapy has been shown to improve quality of life and glucose control in many patients with diabetes opting for this treatment modality.
- Trial name
- NCT02662842
- Testing
- FlowSmart Infusion Set, Current Infusion Set
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Becton, Dickinson and Company
Diabetes, Diabetes Mellitus, Type 1
A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India
This study is conducted in Asia. The aim of the study is to evaluate long term safety and efficacy of Tresiba® (insulin degludec) in patients with diabetes mellitus in routine clinical practice in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02117622
- Testing
- insulin degludec
- Where
- 38 sites in India
- Volunteers
- 1,056 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Diabetes Mellitus, Type 1
PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
The purpose of this clinical investigation is to evaluate the accuracy of the Eversense® continuous Glucose Monitoring System (Eversense® 180 CGM System) measurements when compared with reference standard measurements up to 180…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PROMISE (NCT03808376)
- Testing
- Continuous Glucose Monitoring System
- Where
- 8 sites in United States
- Volunteers
- 208 people
- Sponsor
- Senseonics, Inc.
Diabetes, Diabetes Mellitus, Type 1
The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction
This study is conducted in Europe. The aim of this study is to assess the well-being of patients following treatment with insulin detemir (Levemir®) in subjects with type 1 or type 2 diabetes in whom either initiation of or a…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- CONFIDENCE (NCT01542476)
- Testing
- insulin detemir
- Where
- Netherlands
- Volunteers
- 299 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus
This study is conducted in Europe. The aim of this non-interventional study is to investigate the safety and effectiveness of insulin degludec (Tresiba®) in a real world population with type 1 (T1DM) and 2 (T2DM) diabetes…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- ReFLeCT (NCT02392117)
- Testing
- insulin degludec
- Where
- 8 sites in Denmark, Germany and 6 more
- Volunteers
- 1,262 people
- Sponsor
- Novo Nordisk A/S
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Hypoglycemia
Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator
The trial is a randomized, double-blind First in Human trial to evaluate the safety and tolerability of ZP4207 in healthy volunteers (HV) and in insulin-induced hypoglycemic T1D (type 1 diabetes) subjects as compared to native…
- Trial name
- NCT02367053
- Testing
- ZP4207, Glucagon
- Where
- Germany
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Diabetes, Diabetes Mellitus, Type 1
A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
This survey is conducted in South America. The aim of this survey is to investigate hypoglycaemia among Insulin-treated patients with diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02230631
- Testing
- No treatment given
- Where
- Brazil
- Volunteers
- 704 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with type 1 diabetes.
- Trial name
- NCT02033239
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart 30 in subjects with type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01467323
- Testing
- biphasic insulin aspart, biphasic human insulin
- Where
- 37 sites in Austria, Germany and 3 more
- Volunteers
- 303 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
An Audit of the Impact of Tailored Information Delivered Via a Digital Learning Platform
The study intends to audit the impact of optimal insulin injection technique on clinical parameters and self-care behaviour of insulin treated diabetes patients in a prospective manner with a follow-up of 6 months.
- Trial name
- NCT04007003
- Testing
- training in optimal insulin injection technique
- Where
- 9 sites in Belgium
- Volunteers
- 170 people
- Sponsor
- Becton, Dickinson and Company
Type 2 Diabetes, Type 1 Diabetes
European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.
Accu-Chek® Insight Insulin Pump EU Study is a Multicenter Study to evaluate the Accu-Chek® Insight Insulin Pump in routine practice.
- Trial name
- NCT02105103
- Testing
- Accu-Chek® Insight Insulin Pump
- Where
- 8 sites in Austria, United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 1
Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes
This feasibility study is a prospective, single center, multi-arm study evaluating possible enhancements to the SteadiSet extended wear infusion set.
- Trial name
- NCT07325461
- Testing
- SteadiSet Infusion Set
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tandem Diabetes Care, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.